Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509. We are one of only a few dozen hospitals in the world and just three in California to offer Phase I trials of this first-in-class antibody capable of targeting prostate cancer cells.
The AMG 509 antibody binds to two different proteins, one commonly found on the surface of prostate cancer cells and one on the immune system’s T-cells. “AMG 509 triggers an activation of the patient’s T cells and redirects them to cluster on and eradicate cancer cells,” explains Yung Lyou, MD, a Crosson Cancer Institute genitourinary oncologist who specializes in prostate, kidney and bladder cancers.
Men with metastatic prostate cancer who have not responded to or refused a taxane regimen are currently being enrolled. To learn more about any of the research trials currently underway for a wide range of cancers, please call our oncology research department at (714) 446-5177.
Other content in this Stream
![Personalized cancer peptide vaccine shows remarkable promise against glioblastoma](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1724869136%2FImmune-system-T-cells-attacking-cancer-cells-AdobeStock_707210408-med-res-780x350_as9m4d.jpg&size=1&version=1724882405&sig=93a404bcde535fdc0b781fb78d68c48d&default=hubs%2Ftilebg-blogs.jpg)
A novel peptide vaccine against glioblastoma, a deadly brain tumor, is offering hope to some patients thanks to the work of an international effort including Providence's Santosh Kesari, MD, PhD.
![Examining the efficacy and safety of weight loss medications in the real world](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1723073906%2FWeight_loss1_zfcgm7.png&size=1&version=1723573011&sig=b07972101e8bb8e13a08ca98f023fb08&default=hubs%2Ftilebg-blogs.jpg)
A first-of-its-kind study on the efficacy and safety of weight loss medications in the real world is helping to provide clinicians with new is helping to provide clinicians with valuable new evidence.
![The evolution of cancer immunotherapy: Dr. Urba shares his insights](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1719425901%2FAdobeStock_601395351_ccxtr0.jpg&size=1&version=1719609086&sig=9d3a716ddc1f1d9cf0747924540642bd&default=hubs%2Ftilebg-blogs.jpg)
Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.
![Providence launches groundbreaking study to elevate real-world use of multi-cancer early detection](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1717188418%2Fitemeditorimage_65bd601632c29-1904260.png&size=1&version=1719322471&sig=11801712543fe0dc21a7d0feb1425cb8&default=hubs%2Ftilebg-blogs.jpg)
Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.
![2023 research report highlights breadth and impact of research at Providence](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NDc5YTQzODZjMjUuanBnJnZlcnNpb249MDAwMCZzaWc9ZDJmYzU1MzQ0N2JlYTA4YjgwMzczOTA1ZDllMDMzZGE%25253D&size=1&version=1716229773&sig=18bed8556ca5b79ad7e3127794d3aaeb&default=hubs%2Ftilebg-blogs.jpg)
Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report
![Providence Swedish helps tackle Snohomish County overdose crisis from emergency departments](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1717366768%2FNorth_Puget_Sound_Photo_7_METH-OD_Treatment_b8o07f.png&size=1&version=1724952230&sig=89c039ddb1f4a3ed6683ba5993446958&default=hubs%2Ftilebg-blogs.jpg)
In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.
![With the potential to transform cancer diagnostics, Providence contributes to innovative AI-powered digital pathology model](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NGUwMDhjOWM1ZTguanBnJnZlcnNpb249MDAwMCZzaWc9NTZhZmQ0MDg1YzgyYzRkY2E3YjBiNTMwZDVmOThmY2Q%25253D&size=1&version=1717451792&sig=c8ca53d5d3cb386afe4c52adc245ae82&default=hubs%2Ftilebg-blogs.jpg)
A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.
![Cancer studies seek to harness the power of the immune system](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NDc5MmJkYjg4YjcuanBnJnZlcnNpb249MDAwMCZzaWc9MjZiMzcxNGQ2ODk3ZTBlOTM5NmFjOTBlMzAyNDdhNTM%25253D&size=1&version=1717001975&sig=a027b7f12a560c4dc6e33e53e9ee38ce&default=hubs%2Ftilebg-blogs.jpg)
Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.
![Providence researchers contribute study findings at ASCO 2024 meeting, May 31- June 3](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fres.cloudinary.com%2Fuf-551983%2Fimage%2Fupload%2Fv1716498294%2FAnnual_Meeting_Stock_Image-747x556_jhymys.png&size=1&version=1718049139&sig=e9f4ec6af51de1bbf60352c7e52ac09d&default=hubs%2Ftilebg-blogs.jpg)
The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.
![Angiosarcoma on the rise: new study reveals implications for cancer care and research](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWViNjlkNDY5NDYucG5nJnZlcnNpb249MDAwMCZzaWc9ZDNkNjAxMzk5YmFkY2U3ZGU2M2YxMTY2NDAyZTkxOWM%25253D&size=1&version=1713313658&sig=faf098071d15281247c6f4c50795f821&default=hubs%2Ftilebg-blogs.jpg)
The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.
![Providence researchers conducted over 2400 studies in 2023, according to new report](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2NDc4MmZmMjAzNWMucG5nJnZlcnNpb249MDAwMCZzaWc9YjRkZDBjOWIyNmY1YmI5YTllODMwN2I2YzUyNjNiYzA%25253D&size=1&version=1716215577&sig=d0a08900a8bc66a6d70ef02f43a696c1&default=hubs%2Ftilebg-blogs.jpg)
The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.
![Improving access to cutting-edge research and clinical trials](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWViNDU2ZTJiZGYucG5nJnZlcnNpb249MDAwMCZzaWc9ZjQzNWZlOWVhMzgzMzZhNjk1ODg0YzYwMDZhZjQ3ZjY%25253D&size=1&version=1713390104&sig=9a52c3d1dbf0e69c354bbc6b35a182b2&default=hubs%2Ftilebg-blogs.jpg)
Two stories of how, together with our industry partners and patients, Providence is working to make the latest trials available to more people who could benefit from them.
![Cutting-edge Research to Create Better Solutions for Prostate Cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWRiNzViNTQ5NzMuanBnJnZlcnNpb249MDAwMCZzaWc9YmQ4YTg1YTVmMmQxOGUxZmVkYWYzNWUwZDQ4NDg3ZWE%25253D&size=1&version=1713223608&sig=8ef743147c990512fd76d2a08b709e94&default=hubs%2Ftilebg-blogs.jpg)
Providence St. Jude Crosson Cancer Institute oncologists are aggressively pursuing new answers to metastatic prostate cancer, including research into an innovative immunotherapy called AMG 509.
![Chasing a Cure for Macular Degeneration](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWRhNGE5OTM1NzEuanBnJnZlcnNpb249MDAwMCZzaWc9MGM5OTgwYzNmNDA0ZDIyN2FkNGIwZjY2NzRlM2M5Y2Q%25253D&size=1&version=1713218792&sig=351cb10af8dcf8797bfbd9ecde6b0fd4&default=hubs%2Ftilebg-blogs.jpg)
When the SpaceX mission returns to earth in April, there will be 80 mice onboard who have spent a month living at the International Space Station. The rodents represent the first investigational ophth
![New vaccine being studied for HPV+ head and neck cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY2MWVkZDQyOTkyNzkuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPTIwMWIxOTFmN2FiNzM0MGQ2MDdmMjdjMzFiY2JiMzE4&size=1&version=1715127029&sig=ecb19d8116b5bfc05ff218e92facb634&default=hubs%2Ftilebg-blogs.jpg)
Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.
![How promoting apoptosis in new study may help people with cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZjM2MjI3MjUwN2EuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPTIxNGQxODMwM2VmNDU3MDZjYjg3NjU3NmIyMTQ4MjQx&size=1&version=1711128491&sig=42c0d07122db1165f0c8a1b33509979b&default=hubs%2Ftilebg-blogs.jpg)
In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.
![In the news: TIME highlights CORE’s long COVID research](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzYzMmRmZDZmM2RiMWQuanBnJnZlcnNpb249MDAwMCZzaWc9ZmVhZTlmMmJlNmM1ZmRjMGE0MGU4YmY5NTU2NzUxZDQ%25253D&size=1&version=1710277600&sig=6d80ca64ab5d0af0b1e376598bad59f0&default=hubs%2Ftilebg-blogs.jpg)
A recent article in TIME magazine features research conducted by CORE and the Providence Research Network into the condition known as long COVID.
![State-of-the-art A-fib treatment debuts at Providence Saint John’s Health Center](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZTkxMDViYzAwNWUuanBnJnZlcnNpb249MDAwMCZzaWc9YjFiYzRmNjkxYWY0MGJkMzcyZDg4NjBhOWMzYjZjODU%25253D&size=1&version=1711479163&sig=af760bf0580d078d8f04d764694f4c1d&default=hubs%2Ftilebg-blogs.jpg)
Four patients are among first in the nation to undergo groundbreaking pulsed field ablation procedure.
![Providence Cancer Institute celebrates historic milestone to finish cancer](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZGZiZGUzYmUwNjQuanBnJnZlcnNpb249MDAwMCZzaWc9YzY5YmEzMDJkYTU5ZTRhYTE2MTBkODZiMGZjOGVlY2I%25253D&size=1&version=1709162404&sig=ef25dfe4219be11181e1178f54f77a88&default=hubs%2Ftilebg-blogs.jpg)
The FDA just approved a new immunotherapy for advanced melanoma. Dr. Walter Urba shares how Providence’s participation in the clinical study shows our standing as a global leader in immuno-oncology.
![Dose-escalation studies aspire to fill gaps in cancer treatment options](https://content.cdntwrk.com/mediaproxy?url=https%3A%2F%2Fcontent.cdntwrk.com%2Ffiles%2FaHViPTcxNTQ2JmNtZD1pdGVtZWRpdG9yaW1hZ2UmZmlsZW5hbWU9aXRlbWVkaXRvcmltYWdlXzY1ZDkzMDRkYjVjZTUuanBlZyZ2ZXJzaW9uPTAwMDAmc2lnPWYxNzI2ODIzNmNlZGRmYjE5OTU4NDVkMmMyNjVhYTlh&size=1&version=1708994593&sig=d4e7c266d395a12f06c40f27b75f7d16&default=hubs%2Ftilebg-blogs.jpg)
Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.